Yagnya Joshi
University of Pennsylvania
4 Papers
24 Citations
Yagnya Joshi is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Viral load & BDNA test. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Multicenter Comparison of Different Real-Time PCR Assays for Quantitative Detection of Epstein-Barr Virus
Randall T. Hayden,Kristin M. Hokanson,Stanley Pounds,Matthew J. Bankowski,Susan Belzer,J. Carr,D. Diorio,Michael Forman,Yagnya Joshi,David R. Hillyard,Richard L. Hodinka,M. N. Nikiforova,Charlotte Romain,Jeffery Stevenson,Alexandra Valsamakis,Henry H. Balfour +15 more
TL;DR: While intralaboratory tracking of patients may yield similar results, data indicate a need for caution when attempting to compare clinical results obtained at different institutions and suggest the potential value to be gained by more standardized testing methodology.
136
Langerhans cell histiocytosis and human herpes virus 6 (HHV-6), an analysis by real-time polymerase chain reaction.
Michael P. Glotzbecker,John P. Dormans,Bruce R. Pawel,Brian P.D. Wills,Yagnya Joshi,Michael Elkan,Richard L. Hodinka +6 more
TL;DR: Frozen biopsy material was obtained from 13 patients with LCH and 20 patients without the disease, suggesting that the prevalence of HHV‐6 in the tissue of LCH patients is the same as that found in tissue from individuals without disease.
21
Epstein-Barr virus and human herpesvirus type 6 infection in patients with psoriasis.
Andrea L. Neimann,Richard L. Hodinka,Yagnya Joshi,Michael Elkan,Abby S. Van Voorhees,Joel M. Gelfand +5 more
TL;DR: The results of this study suggest that neither severe psoriasis alone, nor in combination with immunosuppressive therapy, is associated with an increase in Epstein-Barr virus or human herpesvirus 6 replication in white blood cells.
5
Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT
Priscilla Swanson,Carmen de Mendoza,Yagnya Joshi,Alan Golden,Richard L. Hodinka,Vincent Soriano,Sushil G. Devare,John Hackett +7 more
TL;DR: Analysis of nucleotide mismatches at the primer/probe binding sites for Monitor v1.5, NucliSens, and LCx assays revealed that performance characteristics reflected differences in the level of genetic conservation within the target regions.